C-ZXR8General Proximity
proximity therapeutics, effector discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ZXR8
C-ZXR8C-ZXR8proximity therapeutics, effector discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
🎙️ In this podcast episode, Armand Cognetta opened up about his PhD experience: “In some ways, going through a PhD is harder than building a startup. You have less support, less upside—and yet you push through.” A PhD isn’t just academic training—it’s a masterclass in resilience, deep focus, and navigating uncertainty. Especially in biotech, where technical depth is everything, PhDs are often the most qualified to lead innovation. ✅ If you’ve survived a PhD, you’ve already proven you can build through ambiguity. ✅ Business can be learned—obsession with a problem can’t be taught. ✅ Founders aren’t just dreamers—they’re doers with deep domain conviction.
In this episode of the Nucleate Podcast, Armand Cognetta, CEO of General Proximity, shared a brutally honest truth about startup life: “I used to focus on how high the expected value was. But now? I try to scare people away early. Startups are hard. I’ll take care of you if things go wrong — but I can’t promise smooth sailing.” Founders often oversell the dream. But the best ones? They lead with truth — not hype. ✅ Be honest about the grind. ✅ Build with people who know what they’re signing up for. ✅ Support your team — even when things don’t go as planned.
In our this episode, Armand Cognetta shared something raw: “Being a founder is super hard... you gotta be willing to chew glass. I have the best job in the world - I love what I do so much. But you should be obsessed with something... obsessed with changing the world in some way. If you are, startups are the best way to do that.” This hit home. The founders who make it aren’t running from difficulty—they’re running toward something bigger than themselves. They’re obsessed with a problem, a vision, a change they desperately want to see in the world. ✅ Find your obsession, not just your opportunity. ✅ Embrace the difficulty as proof you’re onto something real. ✅ Let your mission be stronger than your fear of failure.
In this episode of the Nucleate Podcast, Armand Cognetta, founder and CEO of General Proximity, shares his compelling journey from a directionless college student to a biotech entrepreneur. Drawing from personal experiences of academic struggles and scientific curiosity, Armand discusses how his passion for chemical biology and small molecule drug discovery led him to create a groundbreaking proximity therapeutics platform. He candidly explores the challenges of startup life, including early fundraising difficulties, imposter syndrome, and the critical importance of persistence, grit, and maintaining a high bar for talent. Throughout the conversation, Armand emphasizes the value of working on ambitious, world-changing ideas, the power of proximity in biological systems, and the need for founders to stay focused, resilient, and mission-driven. His story is a testament to the transformative potential of scientific innovation and entrepreneurial spirit, offering inspiration for young scie
Need help with back-office admin? Talk to us: https://calendly.com/d/cnfm-rn7-5k6/g.. Top-tier CEOs delegate operations to Chore, reclaiming 100 hours of focused time and saving $240K+ a year. In this video, Armand Cognetta, Founder & CEO of General Proximity, shares how Chore acts as his part-time chief of staff, freeing up 30+ hours/month and giving him back the mental space to focus on fundraising, recruiting, and setting the vision. From onboarding, reimbursements, and accounting checks to building a scalable operations system, Chore takes care of everything that used to slow him down. 💡 If you're a founder still handling ops yourself, this is your sign to delegate smarter. ✅ This video is all about: – The ops work that drains early-stage founders – How Chore replaces full-time ops without the full-time cost – Why operations work is never really “done” – How founders can scale faster by outsourcing admin Follow us ⬇️ LinkedIn: / hirechore Twitter: https://x.com/HireChore
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders General Proximity: Funding, Team & Investors | Startup Intros Home / Organizations / General … eed Felicis Ventures Amino Collective , Balderton Capital , Creandum , Founders Fund , Presight Capital , TMV Announced Deep Dive General Proximity is a seed-stage biotechnology platform company founded in 2019 that pioneers the next generation of induced proximity medicines targeting traditionally undruggable proteins implicated in cancer, cardiometabolic disease, neurodegeneration, and longevity. Its proprietary OmniTAC platform enables precise and selective modulation of d … clude Felicis Ventures, Amino Collective, Balderton Capital, Creandum, Founders Fund, Presight Capital, TMV.
Meet Our Team | General Proximity logo link Team Careers News Proximity pioneers We’ve assembled a world-class team of proximity scientists from Scripps, the Broad Institute, Harvard, MIT, Yale, Oxford, and UCSF, with industry experience across top pharma and biotech institutions such as Lilly, Novartis, AbbVie, Bristol Myers Squibb, Amgen, Genentech, Roche, Alnylam, and Arvinas. Our team SCIENTIFIC ADVISORY BOARD CLINICAL ADVISORS STRATEGIC ADVISORS Read Bio Armand B. Cognetta III, PhD Founder and CEO Read Bio Timothy Herpin, PhD Chief Business Officer Read Bio Andreas Maderna, PhD SVP of Dru
Armand B. Cognetta III, PhD | General Proximity Back to team Armand B. Cognetta III, PhD Founder and CEO , “Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.” linkedin link X(twitter) link Back to team Armand began his biotech career at the then early-stage biotech, Alnylam Pharmaceuticals, as their first intern, where he helped develop an in vivo RNAi quantification technology still in use over a decade later when Alnylam became th
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target induced-proximity oncology deal LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … o” news on 12 Nov 2025, and why does it matter for oncology? The companies will apply General Proximity’s OmniTAC platform to identify effector–target pairs for novel induced-proximity cancer drugs, potentially expanding options beyond classic inhibitors and ADCs. ( PR Newswire release , Reuters/Refinitiv brief ) What is the regulatory path after General Proximity's and Daiichi's “multi-target collaboration,” and what are the next formal steps in the US, UK and EU? This is a
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for ‘Undruggable’ Targets – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Fr
General Proximity | | The Pharmaletter Tuesday 2 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Therapy
Home - Vitalist Bay 0 % Sponsor Join May 14 – 17 2026 Join Longevity's New Capital VITALIST BAY SIGN UP 100+ speakers Lighthaven, Berkeley. 200+ Companies Four days. 150+ workshops & talks 100+ speakers 18 activities & health tests 2026 Speakers Day 1 THU May 14 Main Investors Replacement Adam Gries Founder Vitalism Carsten Charlesworth Postdoctoral Researcher Stanford University Christine Peterson Co-Founder Foresight Institute Daniel Burger Founder Eightsix Science Derya Unutmaz Professor The Jackson Laboratory Dylan McGuire Founder Aleph Surgical Emil Kendziorra Emil Kendziorra … Verdin President and CEO The Buck Institute Jamie Justice Executive Director X-Prize Healthspan Jarod Rutledge Director of Biotechnology Investments Starbloom Capital Jean Hebert Program Director ARPA-H Kayla Barnes-Lentz Founder The Female Longevity Protocol Kris Borer Angel investor krisborer.com Laura Minquini Founder AthenaBIO Nathan Price Professor & Co-Director, Center for Human Healthspan Buck Institute Omri Amirav-Drory General Partner Nfx Bio Patri Friedman Gene … ti-Retirement Club, Beusail longevity forums Danielle Strachman Co-Founder 1517 Fund Elaine Shi Co-Founder and CEO Bodyspec Eli Berlin Co-Founder, COO and CFO Terray Therapeutics Eric Morgen COO BioAge Hank Greely Professor of Law, Genetics Stanford University Jarod Rutledge Director of Biotechnology Investments Starbloom Capital Justin Rebo CEO Kind Biotechnology Karl Pfleger Founder Aging Biotech Info Kelsey Moody CEO, Founder, Angel Investor Ichor Life Sciences Kevin Caldw … tive Armand Cognetta CEO General Proximity Dave Messina General Partner Pioneer Fund Derya Unutmaz Professor The Jackson Laboratory Eli Mohamad Space Biostasis Coalition Fabian Suchy Co-founder, Scientist Nakauchi Lab, Stanford University Farbood Nivi Founder A-List Gloria Eliott Program Manager ARPA-H Greg Fahy Chief Scientific Officer 21st Century Medicine / Intervene Immune Jamie Heywood CEO & Chairman Alden Scientific Jeff Chen Co-founder & CEO Radicle Science Joh … Grua Chief of Staff · BodySpec Roxana Grunenwald Partner, Cofounder · Dorm Room Fund, Biopunk Pasha Gurevich VP Product · Elo Health Lou Hawthorne CEO · Nanotics Motoshi Hayano Associate Professor & CEO · Tokyo University of Science & ASAGI Labs Chong He Partner at LiveBeyond / Principal Investigator · LiveBeyond.ai Jean Hebert Program Di
FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All V … SCO , May 4, 2026 /PRNewswire/ -- FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines. General Proximity has built the first mechanism-agnostic proximity discovery engine centered on scanning the "effectome"—the set of effector proteins … BOUT FREEMIND INVESTMENTS (FMI) FreeMind Investments (FMI) is a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., making direct equity investments while leveraging the non-dilutive funding review process to identify promising life science investment opportunities and bridge the biotech startup "valley of death." ABOUT FREEMIND GROUP Founded in 1999, FreeMind Group is the leading non-dilutive funding consultancy for life … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Next-Gen Proximity Medicines | General Proximity Team Careers News Nothing Programmable medicines for all mankind. is Undruggable Programmable medicines for all mankind. Control Proximity , Control Biology First Principles: All biological processes are driven by proximity. Why don’t our medicines work in the same way? general [jen-rəl] adjective Applicable to all, unbiased We’ve built the first generalized, mechanism-agnostic, proximity discovery engine. Our genomes code for thousands of intricate molecular machines—effector proteins—which regulate all aspects of biology. These include chapero
Startups are hard, do something that matters | Armand Cognetta, CEO & founder General Proximity · Nucleate Podcast
Redefining the Undruggable Thr… - The Bits in Bio Podcast - Apple Podcasts Search Home New Top Charts Search October 28, 2025 36 min Redefining the Undruggable Through Proximity with Armand Cognetta The Bits in Bio Podcast Play Armand Cognetta, founder and CEO of General Proximity, joins us to explore how proximity medicine is revolutionizing drug discovery by targeting proteins once considered impossible to drug. We discuss the evolution beyond PROTACs, being a solo bio-founder in Y Combinator, and Armand's journey from imposter syndrome to raising $16M and winning a $3M ARPA-H grant. From ne
General Proximity and Daiichi Sankyo collaborate on oncology Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Me … General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. Daiichi Sankyo entered the collaboration through its Research Institute, located in Boston in the US state of Massachusetts. Go deeper with GlobalData Reports LOA and PTSR Model - Nanrilkefusp Alfa in Hepatocellular Carcinoma Reports LOA and PTSR Model - Nanrilkefusp Alfa in Ovarian Cancer Go deeper with GlobalData The gold standard of b
Startups are hard, do something that matters | Armand Cognetta, CEO & Founder General Proximity Home About Meet the Team Hidden Layers Podcasts Nucleate Search Join Podcasts Startups are hard, do something that matters | Armand Cognetta, CEO & Founder General Proximity A conversation with Armand Cognetta, CEO & founder of General Proximity Anastasia Janas and Benjamin Arya July 19, 2025 — 6 minutes read Team Table Host Anastasia Janas, Benjamin Arya Editors Jose Zamora Social Media Manager Priya Singhal Short-form Content Creator Caitlin FitzMaurice, Miaoci (Cici) Zhang Listen Appl … f Life & Computer Sciences Subscribe to new posts Subscribe Processing your application Please check your inbox and click the link to confirm your subscription. There was an error sending the email Presented by Nucleate: The Voice of Next Generation Biotech. Social Twitter Links Sign up © Nucleate Signal 2026. An independent publication by Nucleate. You’ve successfully subscribed to Nucleate Signal Welcome back! You’ve successfully signed in. Great! You’ve successful
Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity's strong scientific position and innovation in next-generation induced proximity medicines, and the interest in a potential future strategic collaboration from Daewoong Pharmaceutical. May 4, 2026 Read More Press General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutic … i Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Boston to apply General Proximity’s proprietary OmniTAC™ discovery platform to oncology programs of interest to Daiichi Sankyo. November 12, 2025 Read More Announcement Dr. Margaret Dugan, a Clinical Oncology Drug Development Expert, Joins Our Scientific Advisory Board We are excited to announce that Dr. Margaret Dugan has joined General Proximity's Scientific Advisory Board. Dr. Dugan brings 30+ years … l Myers Squibb (BMS). July 25, 2024 Read More Announcement NIH NCI SBIR Phase I Award We are proud to announce that General Proximity has been awarded a NIH NCI SBIR Phase I grant. This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer. February 1, 2024 Read More Announcement Dr. Margaret Dugan, a Clinical Oncology Drug Development Expert, Jo … l Myers Squibb (BMS). July 25, 2024 Read More Announcement NIH NCI SBIR Phase I Award We are proud to announce that General Proximity has been awarded a NIH NCI SBIR Phase I grant. This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer. February 1, 2024 Read More Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in Gener … i Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Boston to apply General Proximity’s proprietary OmniTAC™ discovery platform to oncology programs of interest to Daiichi Sankyo. November 12, 2025 Read More Press General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable'
Nucleate Podcast Nucleate Podcast Startups are hard, do something that matters | Armand Cognetta, CEO & founder General Proximity Episode Notes In this episode of the Nucleate Podcast, Armand Cognetta, founder and CEO of General Proximity, shares his compelling journey from a directionless college student to a biotech entrepreneur. Drawing from personal experiences of academic struggles and scientific curiosity, Armand discusses how his passion for chemical biology and small molecule drug discovery led him to create a groundbreaking proximity therapeutics platform. He candidly explores the cha
Startups are hard, do something that matters | General Proximity Back to News Startups are hard, do something that matters “Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.” Back to team I n this episode of the Nucleate Podcast, Armand Cognetta, founder and CEO of General Proximity, shares his journey from struggling college student to biotech entrepreneur. Armand discusses how his passion for chemical biology led him to create a g
The Bits In Bio Letter - October November 3rd 2025 Bits in Bio Subscribe Sign in The Bits In Bio Letter - November 3rd 2025 Updates From and Around the Bits in Bio Community Vincent Alessi , Erle Holgersen , Charlene Her , and Ansgar Lange Nov 04, 2025 4 Share 📢 Highlights Anthropic Bets Life Sciences Needs AI That’s Never Held a Pipette NIH’s $87M Organoid Center Takes Aim at Drug Development’s 90% Failure Rate Novartis Pays $12B Premium for Muscle-Directed RNA Platform and Three Clinical Shots Not yet a member of our super awesome slack community of ~11,000? Join HERE 🤗 ✨ Special Announcem … c: as pharma realizes that knowing a protein’s shape is just step one, the real prize is accurately predicting how drugs will nestle into binding pockets—a nuance that could mean the difference between a blockbuster and a clinical failure. With both computational giants now competing on drug-specific applications rather than pure academic metrics, the structural biology wars are officially entering their pharmaceutical phase. Owkin’s K-PRO becomes biopharma’s first full stack … ct! Is anyone shocked? Tune into the conversation here ! 🏢 New Job Openings VC Fellowship at Forbion BioEconomy Head of Large Libraries at Cradle Scientific Data Solutions Lead at Ontoforce Senior ML Engineer at Syntensor Director of Chemistry at Glyphic Biotechnologies Bioinformatics Engineer at the Nucleic Acid Observatory 🙋 🙏 Community Asks Feedback: How is the Newsletter doing? We’re trying different formats/content. In case the hyperlink above didn’t get your attentio
The Bits In Bio Letter - September 25th 2025 Bits in Bio Subscribe Sign in The Bits In Bio Letter - September 25th 2025 Updates From and Around the Bits in Bio Community Vincent Alessi , Erle Holgersen , and Charlene Her Sep 26, 2025 1 Share 📢 Highlights First AI-generated genomes create viable bacteria-killing phages Lilly opens $1B research vault to its portfolio of biotech startups through new AI platform - TuneLabs LB Pharma breaks the IPO drought with an increased $285M Nasdaq debut Not yet a member of our super awesome slack community of ~10,000? Join HERE 🤗 ✨ Special Announcement! ✨ I … riational AI has entered a collaboration with Merck worth up to $349 million to apply its Enki™ generative AI platform against two undisclosed “challenging therapeutic targets.” The deal structure—upfront payment plus milestones with no royalties—validates the generative foundation model approach to drug discovery, particularly impressive given Variational AI operates without wet labs and competes against established players like Insilico Medicine and Exscientia. Merck will f
Armand B. Cognetta III | Substack Home Subscriptions Chat Activity Explore Profile Create Vim Armand B. Cognetta III @cognetta Making high-utility medicines at General Proximity ( prox.bio ) Vim Suffertember General Proximity 6 7.7K+ subscribers Subscribe Message Activity Posts Likes & Replies Reads (335) Get app This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
General Proximity | Armand B. Cognetta III | Substack General Proximity Subscribe Sign in Home General Proximity Archive How to solve aging What the longevity field is missing Published on Vim • Mar 6 The magic of doing hard things a podcast interview with me & Nucleate Published on Vim • Jul 12, 2025 General Proximity generalproximity.bio blog Subscribe General Proximity Subscribe About Archive Sitemap © 2026 General Proximity · Privacy ∙ Terms ∙ Collection notice Start your Substack Get the app Substack is the home for great culture This site requires JavaScript to run correctly. Please
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform November 13, 2025 | 2 min read Twitter LinkedIn Facebook Email Print - The collaboration will leverage General Proximity's OmniTAC ™ platform to iden … i Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Boston to apply General Proximity's proprietary OmniTAC ™ discovery platform to oncology programs of interest to Daiichi Sankyo. Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The approach uses small molecules to bring two proteins into close physical proximity and subseque … intelligence Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling May 21, 2026 · 3 min read · Tristan Manalac Rare diseases BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication May 21, 2026 · 2 min read · Tristan Manalac Drug Development Beam one-ups Wave as both show promise of genetic editing for AATD May 20, 2026 · 2 min read · … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity May 4, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Investment reflects General Proximity's strong scientific position and innovation in next-generation induced proximity medicines, and the interest in a pote … SCO , May 4, 2026 /PRNewswire/ -- FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines. General Proximity has built the first mechanism-agnostic proximity discovery engine centered on scanning the "effectome"—the set of effector proteins … BOUT FREEMIND INVESTMENTS (FMI) FreeMind Investments (FMI) is a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., making direct equity investments while leveraging the non-dilutive funding review process to identify promising life science investment opportunities and bridge the biotech startup "valley of death." ABOUT FREEMIND GROUP Founded in 1999, FreeMind Group is the leading non-dilutive funding consultancy for life … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin